• P J Kulka, M Tryba, and S Lange.
• Abteilung für Anästhesiologie und Intensivmedizin Evangelisches Krankenhaus Oberhausen. Peter.Kulka@ruhr-uni-bochum.de
• Anasthesiol Intensivmed Notfallmed Schmerzther. 2001 Mar 1; 36 (3): 143-53.

AbstractThe serine-protease-inhibitor antithrombin III (AT III) has often been recommended for the therapy of septic patients as it provides anticoagulant and antiinflammatory actions. In animal studies the prophylactic treatment with AT III in a dose > 250 U/kg prevented the development of disseminated intravascular coagulopathy and vital organ dysfunction during sepsis and lowered the mortality rate. In clinical studies with septic patients therapy usually was started several hours after the start of the disease in dosages much lower than those used in animal studies. In these patients AT III-therapy improved laboratory changes of disseminated intravascular coagulopathy but was unable to lower the mortality rate. Hereditary AT III deficiency, lack of heparin effect due to low AT III levels, disseminated intravascular coagulation disorders are indications for the use of AT III while beneficial effects of AT III in patients suffering from SIRS, sepsis or septic shock have not yet been demonstrated.

14 keywords...

hide…